Plamotamab

Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20+ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo[1][2].

Product Specifications

CAS Number

[2138442-31-4]

Product Name Alternative

XmAb-13676

UNSPSC

12352203

Target

CD20; CD3

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/plamotamab.html

Purity

99.12

Solubility

10 mM in DMSO

Smiles

[plamotamab]

Molecular Weight

(124.88 kDa)

References & Citations

[1]Parrondo RD, et al. Plamotamab (XmAb®13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia. Leuk Lymphoma. 2022 Mar;63 (3) :738-742. |[2]Luo Peter PZ, et al. Anti-CD3 antibodies and methods of use thereof. World Intellectual Property Organization, WO2022170740 A1. 2022-08-18.